Does GOSERELIN Cause Second primary malignancy? 10 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Second primary malignancy have been filed in association with GOSERELIN (ZOLADEX). This represents 0.2% of all adverse event reports for GOSERELIN.
10
Reports of Second primary malignancy with GOSERELIN
0.2%
of all GOSERELIN reports
0
Deaths
6
Hospitalizations
How Dangerous Is Second primary malignancy From GOSERELIN?
Of the 10 reports, 6 (60.0%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for GOSERELIN. However, 10 reports have been filed with the FAERS database.
What Other Side Effects Does GOSERELIN Cause?
Death (1,293)
Malignant neoplasm progression (935)
Metastases to bone (397)
Neutropenia (339)
Fatigue (309)
Off label use (272)
Metastases to liver (264)
Hot flush (263)
Asthenia (213)
Arthralgia (190)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which GOSERELIN Alternatives Have Lower Second primary malignancy Risk?
GOSERELIN vs GRAMICIDIN
GOSERELIN vs GRAMICIDIN\NEOMYCIN\POLYMYXIN B
GOSERELIN vs GRAMICIDIN\POLYMYXIN B
GOSERELIN vs GRANISETRON
GOSERELIN vs GRANULOCYTE COLONY-STIMULATING FACTOR NOS